Stock Report

Download full stock data and analysis for free Last Updated: 04-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Liminal BioSciences - ADR Key Ratios

Stock Card factsheet share-fund-plan-icon

$8.50

$0.00 (0.00%)

As on 26-Sep-2023 09:30EDT

Market cap

info icon

$28 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0.4

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -17.65 -28.66 -12.92 26.97 -61.08
EBIT -23.41 -7.79 19.52 19.22 11.44
Net Profit -19.52 -221.87 -101.20 25.89 14.81
EPS -19.52 -192.26 -99.35 26.05 14.87
Book Value -- -- -15.69 -35.60 -59.37
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-22Dec-21
EBIT-Margin info -6,257.49-4,661.44-6,946.95-8,223.19-7,707.15
Net Margin info ----71.95----
Return on equity info -135.14-406.14-2.15-73.35-137.10
Return on Capital info -61.70-105.28---40.98-44.95
Return on Assets info -52.03-86.380.51-32.76-36.96
Debt to Equity (x) info ----0.000.041.43

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
--
-40.98
-44.95
-99.16
-207.14
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-2.15

Higher than Peers by 13.83

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
-2.15
-73.35
-137.10
-194.97
-1,027.64
Peer Median
-15.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

0.51

Higher than Peers by 12.36

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
0.51
-32.76
-36.96
-86.35
-174.80
Peer Median
-11.85
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-6,946.95

Lower than Peers by 6,919.90

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
-6,946.95
-8,223.19
-7,707.15
-2,842.12
-4,295.07
Peer Median
-27.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

71.95

Higher than Peers by 104.64

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
71.95
-7,210.97
-7,008.24
-3,682.15
-4,776.18
Peer Median
-32.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Higher than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-12.92

Lower than Peers by 46.89

Year on year growth in net sales

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
-12.92
-0.38
-0.81
-0.32
-0.90
Peer Median
33.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

19.52

Higher than Peers by 44.78

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
19.52
33.46
47.43
55.24
-85.51
Peer Median
-25.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-101.20

Lower than Peers by 79.62

Year on year growth in profit after tax

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
-101.20
35.83
63.10
47.85
-19.89
Peer Median
-21.58
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-99.35

Lower than Peers by 93.18

Year on year growth in earnings per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
-99.35
0.36
0.67
0.55
0.96
Peer Median
-6.17
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-21.22

Lower than Peers by 18.32

Year on year growth in book value per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
-21.22
--
--
--
--
Peer Median
-2.89
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
--
0.04
1.43
3.20
0.46
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.03

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
0.03
0.02
0.17
0.30
0.08
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

2.78

Lower than Peers by 6.33

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
2.78
4.09
6.20
3.07
3.03
Peer Median
9.11
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

2.78

Lower than Peers by 6.33

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
2.78
--
6.20
2.68
2.79
Peer Median
9.11
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-19.60

Lower than Peers by 20.32

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
-19.60
-30.59
-7.83
-10.81
-14.99
Peer Median
0.72
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

160.16

Higher than Peers by 137.41

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
160.16
293.52
166.10
117.67
271.21
Peer Median
22.75
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.01

Lower than Peers by 0.05

Sales / Average Total Assets

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
0.01
0.00
0.01
0.02
0.04
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
--
1,022.43
1,411.86
947.15
1,239.09
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
--
--
--
1,518.94
1,292.85
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
--
--
--
1,765.08
2,088.19
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Liminal BioSciences - ADR
--
--
--
701.02
443.75
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...